Eldre publikasjoner

Et utvalg lungekreftpublikasjoner med norske forfattere de siste år. Send info om manglende eller nye publikasjoner til Webredaktør.

2012
Donnem T, Bremnes RM, Busund LT, Andersen S, Pezzella F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer.
J Thorac Dis. 2012 Apr 1;4(2):212-3.PMID: 22833829

Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland A, Brustugun OT. Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations. J Thorac Oncol. 2012 Sep;7(9):1471-3. PMID: 22895145

Rud AK, Lund-Iversen M, Berge G, Brustugun OT, Solberg SK, Mælandsmo GM, Boye K. Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer. 2012 Aug 1;12(1):333. PMID: 22853000

Fløtten O, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 3. doi: 10.1038/bjc.2012.284. PMID:22759880.
 
Strand TE. More emphasis on resection rates! J Thorac Oncol. 2012 Jul;7(7):1067-8. PMID: 22706606.
 
Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L. [Mutation testing for non-small-cell lung cancer]. Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. Norwegian. PMID: 22562326.
 
Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A, Martinez-Zubiaurre I. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol. 2012 Apr 13;7(1):59. PMID: 22500976.
 
Strand TE, Bartnes K, Rostad H. National trends in lung cancer surgery. Eur J Cardiothorac Surg. 2012 Aug;42(2):355-8. Epub 2012 Mar 7. PMID: 22402451.
 
Nordlund MS, Stieber P, Brustugun OT, Warren DJ, Paus E. Characteristics and clinical validity of two immunoassays for ProGRP. Tumour Biol. 2012 Aug;33(4):1105-13. Epub 2012 Mar 8. PMID: 22399443.

Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E. Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors. Acta Oncol. 2012 May;51(5):603-9. PMID: 22304490.
 
Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One. 2012;7(1):e29671. Epub 2012 Jan 25. PubMed PMID: 22295063.
 
Nieder C, Tollåli T, Norum J, Pawinski A, Bremnes RM. A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer. Anticancer Res. 2012 Jan;32(1):189-94. PMID: 22213306.

Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT. Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients. J Thorac Oncol. 2012 Jan;7(1):57-63. PMID: 21900838.

Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644. PMID: 22327624.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer. 2012 Feb;75(2):235-41. PMID: 21764478.

 
2011
Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol. 2011 Nov;6(11):1810-7. PubMed PMID: 21964531.
 
Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL,  Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011 Nov 1;17(21):6847-57. Epub 2011 Sep 14. PubMed PMID: 21918169.
 
Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011;6(8):e23847. Epub 2011 Aug 22. PubMed PMID: 21887331; PubMed Central PMCID: PMC3161788.
 
Knudtsen IS, Rødal J, Brustugun OT, Helland Å, Skretting A, Malinen E. Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study. Acta Oncol. 2011 Aug;50(6):889-96. PubMed PMID: 21767189.
 
Tekpli X, Zienolddiny S, Skaug V, Stangeland L, Haugen A, Mollerup S. DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int J Cancer. 2011 Dec 31. doi: 10.1002/ijc.27421. [Epub ahead of print] PubMed PMID: 22213191.

Huang YT, Lin X, Liu Y, Chirieac LR, McGovern R, Wain J, Heist R, Skaug V, Zienolddiny S, Haugen A, Su L, Fox EA, Wong KK, Christiani DC. Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16345-50. Epub 2011 Sep 12. PubMed PMID: 21911369; PubMed Central PMCID: PMC3182687.

Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011 Feb;71(2):123-9. Epub 2010 May 14. PubMed PMID: 20471133.

Huang YT, Lin X, Chirieac LR, McGovern R, Wain JC, Heist RS, Skaug V, Zienolddiny S, Haugen A, Su L, Christiani DC. Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. PLoS One. 2011;6(8):e22961. Epub 2011 Aug 2. PubMed PMID: 21829676; PubMed Central PMCID: PMC3149069.

Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP, Meese E. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 2011 May-Jun;8(3):506-16. Epub 2011 May 1. PubMed PMID: 21558792.

Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, Mawrin C, Parise O Jr, Sasaki H, Tsuchiya N, Dragani TA. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev. 2011 Jul;20(4):340-7. PubMed PMID: 21412156.

Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathé EA, Takenoshita S, Yokota J, Haugen A, Harris CC. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011 Apr 1;17(7):1875-82. Epub 2011 Feb 24. PubMed PMID: 21350005.

Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A, Mollerup S. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer. 2011 Mar;71(3):264-70. Epub 2010 Oct 15. PubMed PMID: 20951464.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun;1(1):78-89. PubMed PMID: 22328973; PubMed Central PMCID: PMC3274752.

Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Tarón M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R, Camps C. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2011 Jul;12(4):224-30. doi: 10.1016/j.cllc.2011.03.023. Epub 2011 Apr 24. PubMed PMID: 21726821.
 
Berg A, Brustugun OT, Lund-Iversen M, Helland Å. Palmar bullous blistering induced by erlotinib. J Thorac Oncol. 2011 May;6(5):954. PubMed PMID: 21623268.
 
Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol. 2011 May;6(5):947-50. PubMed PMID: 21623266.
 
Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Stenvold H, Busund LT, Bremnes RM. Correlation and coexpression of HIFs and NOTCH markers in NSCLC. Anticancer Res. 2011 May;31(5):1603-6. PubMed PMID: 21617216.
 
Andersen S, Donnem T, Al-Shibli K, Al-Saad S, Stenvold H, Busund LT, Bremnes RM. Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One. 2011;6(5):e19773. Epub 2011 May 16. PubMed PMID: 21603628; PubMed Central PMCID: PMC3095634.
 
Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer. 2011 Mar;12(2):106-15. doi: 10.1016/j.cllc.2011.03.005. Epub 2011 Apr 11. PubMed PMID: 21550557.
 
Turzer M, Brustugun OT, Waldeland E, Helland A. Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity. Case Rep Oncol. 2011 Jan 21;4(1):25-34. PubMed PMID: 21526003; PubMed Central PMCID: PMC3082486.
 
Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, Busund LT. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer. 2011 Jul 15;117(14):3193-200. doi: 10.1002/cncr.25907. Epub 2011 Jan 24. PubMed PMID: 21264844.
 
Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sánchez JJ, Camps C. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Feb;6(2):286-90. PubMed PMID: 21252717.
 
Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Al-Shibli K, Andersen S, Stenvold H, Bremnes RM, Busund LT. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med. 2011 Jan 10;9:6. PubMed PMID: 21219656; PubMed Central PMCID: PMC3023703.
 
Sagerup CM, Småstuen M, Johannesen TB, Helland Å, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax. 2011 Apr;66(4):301-7. Epub 2011 Jan 2. PubMed PMID: 21199818.
 
Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2011 Apr;6(4):824-33. Review. PubMed PMID: 21173711.
 
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT,Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010 Dec 15;2(62):62ra93. Erratum in: Sci Transl Med. 2012 Apr 18;4(130):130er2. Sci Transl Med. 2011 Jan 19;3(66):66er2. PubMed PMID: 21160078.
 
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011 Jan;6(1):209-17. Review. PubMed PMID: 21107292.
 
Strand TE, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J. Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):133-41. Epub 2010 May 6. PubMed PMID: 20452137.
 
Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer. 2011 Jun;72(3):294-302. Epub 2010 Nov 13. PubMed PMID: 21075472.
 
Naalsund A, Rostad H, Strøm EH, Lund MB, Strand TE, Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg. 2011 Apr;39(4):565-9. PubMed PMID: 20888248.
 
2010
Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J Thorac Oncol. 2010 Oct;5(10):1536-43. PubMed PMID: 20802349.
 
Turzer M, Brustugun OT, Helland A. Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses. Case Rep Oncol. 2010 Jun 26;3(2):195-201. PubMed PMID: 20740196; PubMed Central PMCID: PMC2919999.
 
Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010 Dec 15;116(24):5676-85. doi: 10.1002/cncr.25551. Epub 2010 Aug 24. PubMed PMID: 20737536.
 
Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010 Sep 15;116(18):4318-25. PubMed PMID: 20549821.
 
Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS. 2010 May;118(5):371-82. PubMed PMID: 20477813.
 
Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen C, Jordhøy M. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010 Aug;46(12):2225-34. Epub 2010 May 12. PubMed PMID: 20471248.
 
Holmberg L, Sandin F, Bray F, Richards M, Spicer J, Lambe M, Klint A, Peake M, Strand TE, Linklater K, Robinson D, Møller H. National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax. 2010 May;65(5):436-41. PubMed PMID: 20435867.
 
Olivo-Marston SE, Mechanic LE, Mollerup S, Bowman ED, Remaley AT, Forman MR, Skaug V, Zheng YL, Haugen A, Harris CC. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis. 2010 Oct;31(10):1778-86. Epub 2010 Aug 20. PubMed PMID: 20729390; PubMed Central PMCID: PMC2981456.

Truong T, Hung RJ, Amos CI, Wu X, Bickeböller H, Rosenberger A, Sauter W, Illig T, Wichmann HE, Risch A, Dienemann H, Kaaks R, Yang P, Jiang R, Wiencke JK, Wrensch M, Hansen H, Kelsey KT, Matsuo K, Tajima K, Schwartz AG, Wenzlaff A, Seow A, Ying C, Staratschek-Jox A, Nürnberg P, Stoelben E, Wolf J, Lazarus P, Muscat JE, Gallagher CJ, Zienolddiny S, Haugen A, van der Heijden HF, Kiemeney LA, Isla D, Mayordomo JI, Rafnar T, Stefansson K, Zhang ZF, Chang SC, Kim JH, Hong YC, Duell EJ, Andrew AS, Lejbkowicz F, Rennert G, Müller H, Brenner H, Le Marchand L, Benhamou S, Bouchardy C, Teare MD, Xue X, McLaughlin J, Liu G, McKay JD, Brennan P, Spitz MR. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst. 2010 Jul 7;102(13):959-71. Epub 2010 Jun 14. PubMed PMID: 20548021; PubMed Central PMCID: PMC2897877.

Truong T, Sauter W, McKay JD, Hosgood HD 3rd, Gallagher C, Amos CI, Spitz M, Muscat J, Lazarus P, Illig T, Wichmann HE, Bickeböller H, Risch A, Dienemann H, Zhang ZF, Naeim BP, Yang P, Zienolddiny S, Haugen A, Le Marchand L, Hong YC, Kim JH, Duell EJ, Andrew AS, Kiyohara C, Shen H, Matsuo K, Suzuki T, Seow A, Ng DP, Lan Q, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Constantinescu V, Bencko V, Foretova L, Janout V, Caporaso NE, Albanes D, Thun M, Landi MT, Trubicka J, Lener M, Lubinski J; EPIC-lung, Wang Y, Chabrier A, Boffetta P, Brennan P, Hung RJ. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis. 2010 Apr;31(4):625-33. Epub 2010 Jan 27. PubMed PMID: 20106900; PubMed Central PMCID: PMC2847090.

Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen C, Jordhøy M. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010 Aug; 46 (12): 2225-34.

Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J. 2010 Dec;10(6):513-23. Epub 2010 Feb 16. PubMed PMID: 20157331.
 
Strand TE, Rostad H, Wentzel-Larsen T, von Plessen C. A population-based evaluation of the seventh edition of the TNM system for lung cancer. Eur Respir J. 2010 Aug;36(2):401-7. Epub 2010 Jan 14. PubMed PMID: 20075046.
 
2009
Sagerup CM, Brustugun OT, Jørgensen L. [A 67-year old man with right arm paresthesias]. Tidsskr Nor Laegeforen. 2009 Dec 17;129(24):2613-5. Norwegian. PubMed PMID: 20029558.
 
Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res. 2009 Oct;29(10):4175-83. PubMed PMID: 19846969.
 
Helland A, Brustugun OT. [Lung cancer in smokers and never-smokers]. Tidsskr Nor Laegeforen. 2009 Sep 24;129(18):1859-62. Review. Norwegian. PubMed PMID: 19844277.
 
Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009 Sep;55(3):301-12. PubMed PMID: 19723145.
 
Nieder C, Bremnes RM, Andratschke NH. Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol. 2009 Nov;4(11):1337-41. PubMed PMID: 19701108.
 
Uppstad H, Øvrebø S, Haugen A, Mollerup S. Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol Lett. 2010 Feb 1;192(2):221-8. Epub 2009 Oct 30. PubMed PMID: 19879933.

Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, Haugen A. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis. 2009 Aug;30(8):1368-71. Epub 2009 May 22. PubMed PMID: 19465454.

Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis. 2009 Jul;30(7):1186-92. Epub 2009 May 21. PubMed PMID: 19461122.

Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, Haugen A, Wu MC, Wang Z, Su L, Asomaning K, Christiani DC. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2009 Jun 1;27(16):2660-7. Epub 2009 May 4. PubMed PMID: 19414679; PubMed Central PMCID: PMC2690391.

18: Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, Nosotti M, Santambrogio L, Incarbone M, Alloisio M, Calabrò E, Pastorino U, Skaug V, Haugen A, Taioli E, Dragani TA. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009 Jun 15;124(12):2880-5. PubMed PMID: 19296538.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24.

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten Ø, Amundsen T, von Plessen C, Wang M, Sundstrøm S. A prospective phase ll study: Highdose pemetrexed as second-line chemotherapy inn small-cell lung cancer. Lung Cancer. 2009 Jan;63(1):88-93.

2008
von Plessen C, Strand TE, Wentzel-Larsen T, Omenaas E, Wilking N, Sundstrøm S, Sørenson S. Effects of third generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway - a national study. Thorax. 2008 Oct;63(10):866-71.

Helbekkmo N, Aasebø U, Sundstrøm S, Brunsvig P, von Plessen C, Bremnes RM. Treatment outcome in performance status 2 advanced NSCLC patients admiistered platinum based combination chemotherapy. Lung Cancer. 2008 Nov;62(2):253-60.

Hermes A, Bergmann B, Bremnes R, Ek Lars, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sørenson S. Irinotecan plus Carboplatin versus oral Etoposide in Extensive mall-Cell Lung Canser: A randomized Phase lll Trial. J Clin Oncol, 26:4261-67, 2008.

2007
Helbekkmo N, Sundstrøm SH, Aasebø U, Brundsvig P Fr, von Plessen C, Hjelde HH, Garpestad OK, Bailey A and Bremnes RM, for the Norwegian Lung Canser Study Group. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97;283-89, 2007.

2006
Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S, for the Norwegian Lung Cancer Study Group. Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short- or Long-Course Radiotherapy? J Thoracic Oncol, vol 1, 8; 816-24, 2006.

von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrøm S, Gilleryd M, Stephens R, Vilsvik J, Aasebø U, Sørenson S, for the Norwegian Lung Cancer Study Group. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95;966-73, 2006.

2005
Brunsvig PF, Hatlevoll R, Berg R, Lauvang G, Øwre K, Wang M, Aamdal S. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A phase I/II study with 5 years' follow-up. Lung Cancer, 50:97-105, 2005).

Sundstrøm S, Bremnes R, Brunsvig P, Aasebø U, Kleppp O, Fayers PM, Kaasa S; for the Norwegian Lung Cancer Study Group. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data form a prospective randomised study. Radioth Oncol, 75:141-148, 2005.

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Amdal S; For the Norwegian Lung Cancer Study Group. Second-line chemotherapy in recurrent small cell lung cancer. Result from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer, 48: 251-261, 2005.

2004
Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers P, Kaasa S; For the Norwegian Lung Cancer Study Group. The effect of hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: Results from a national phase III trial. J Clin Oncol 22; 801-810, 2004.

2003
Bremnes RM, Sundstrøm S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S; For the Norwegian Lung Cancer Study Group. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5-year follow-up. Lung Cancer, 39: 303-313, 2003.

2002
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; For the Norwegian Lung Cancer Study Group. Cisplatin and Etoposide Regimen Is Superior to Cyclophoshamide, Epirubicin, and Vincristin Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years Follow-Up. J Clin Oncol 20: 4665-4672, 2002.

2001
Bremnes RM, Sundstrøm S, Vilsvik J, Aasebø U; For the Norwegian Lung Cancer Study Group. Multicenter Phase II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 19: 3532-3538, 2001.

Bremnes RM, Hirsch FR. Screening for lungekreft – hva nå? Tidsskr Nor Lægeforen 121: 1600-1604, 2001.